December 4, 2013 / 2:00 PM / 4 years ago

Medicines Co buys antibiotic-maker Rempex

Dec 4 (Reuters) - Medicines Co on Wednesday said it acquired privately held Rempex Pharmaceuticals Inc, which develops medicines against drug-resistant bacteria, for $140 million and potential future milestone payments of up to $334 million.

Medicines Company said it acquires several anti-infective drugs as part of the deal, including a promising experimental medicine called Carbavance that has completed early-stage trials.

The company said it will continue to develop other experimental drugs from Rempex that also treat gram-negative bacteria in hospital settings.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below